MG
Montreal Gazette
›Fobi Files 2025 Annual and Q1 & Q2 2026 Interim Financial Statements›Brookfield Business Corporation Completes 2025 Annual Filings›Organigram Announces Shareholder Approval of Acquisition of Sanity Group GmbH and Results of its Annual General and Special Meeting›Montreal mayor, police chief condemn misogyny toward female officer›AGI Announces Resignation of Chief Financial Officer›Armstrong Fluid Technology Appoints Danilo Elez as Chief Executive Officer›Ontario home building and development industry hails historic federal and provincial announcement on development charges›Todd: Canadiens serve notice they can beat any team in the East›Elysian Strengthens Technology Leadership with Appointment of Chief Technology Officer›eXp Realty Recognizes 2025’s Top Producers›Harvest ETFs Announces Final March 2026 Cash Distribution for the Harvest Canadian T-Bill ETF›Operational Innovation at Milton Hydro Recognized with Provincial Industry Award›Jameson Welcomes Music Icon J Balvin as the Newest Member of the Family›Wawanesa invests in community-led initiatives building wildfire resilience›Metro Systems Complete™: Your Partner for Flawless Flooring Projects›Qodo Raises $70M to Accelerate Fight Against Software Slop From OpenClaw and Claude Code›Susan Pirzchalski Appointed Head of Robotics Engineering›Who Has the Worst Roads in North America? Nokian Tyres Invites Drivers To Vote›Club Vita Announces Key Promotions to Strengthen North American Leadership›Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
Last updated: May 3, 2026, 11:00 a.m.